These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 38733184)
21. Bibliometric study of immunotherapy for hepatocellular carcinoma. Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H Front Immunol; 2023; 14():1210802. PubMed ID: 37600802 [TBL] [Abstract][Full Text] [Related]
22. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape. Mody K; Abou-Alfa GK Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732 [TBL] [Abstract][Full Text] [Related]
23. Non-surgical treatment of hepatocellular carcinoma. Lin DY; Lin SM; Liaw YF J Gastroenterol Hepatol; 1997 Oct; 12(9-10):S319-28. PubMed ID: 9407353 [TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for hepatocellular carcinoma. Li S; Yang F; Ren X Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545 [TBL] [Abstract][Full Text] [Related]
25. Systemic therapies for hepatocellular carcinoma. Ge S; Huang D Drug Discov Ther; 2015 Oct; 9(5):352-62. PubMed ID: 26632544 [TBL] [Abstract][Full Text] [Related]
26. [The companion diagnostics of targeted therapy and immunotherapy for hepatocellular carcinoma]. Huang XW; Liu SH; Zhao JM Zhonghua Gan Zang Bing Za Zhi; 2022 Sep; 30(9):912-917. PubMed ID: 36299182 [TBL] [Abstract][Full Text] [Related]
27. [Systemic therapeutic strategies for hepatocellular carcinoma: current status and prospects]. Yuan ZG; Ye SL Zhonghua Gan Zang Bing Za Zhi; 2024 Jun; 32(6):565-571. PubMed ID: 38964901 [TBL] [Abstract][Full Text] [Related]
28. Goals and targets for personalized therapy for HCC. Couri T; Pillai A Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478 [TBL] [Abstract][Full Text] [Related]
29. Hepatocellular carcinoma in the era of immunotherapy. Sim HW; Knox J Curr Probl Cancer; 2018; 42(1):40-48. PubMed ID: 29150141 [TBL] [Abstract][Full Text] [Related]
30. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Cervello M; McCubrey JA; Cusimano A; Lampiasi N; Azzolina A; Montalto G Oncotarget; 2012 Mar; 3(3):236-60. PubMed ID: 22470194 [TBL] [Abstract][Full Text] [Related]
31. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Giglia JL; Antonia SJ; Berk LB; Bruno S; Dessureault S; Finkelstein SE Cancer Control; 2010 Apr; 17(2):120-9. PubMed ID: 20404795 [TBL] [Abstract][Full Text] [Related]
32. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Yarchoan M; Agarwal P; Villanueva A; Rao S; Dawson LA; Llovet JM; Finn RS; Groopman JD; El-Serag HB; Monga SP; Wang XW; Karin M; Schwartz RE; Tanabe KK; Roberts LR; Gunaratne PH; Tsung A; Brown KA; Lawrence TS; Salem R; Singal AG; Kim AK; Rabiee A; Resar L; Hoshida Y; He AR; Ghoshal K; Ryan PB; Jaffee EM; Guha C; Mishra L; Coleman CN; Ahmed MM Cancer Res; 2019 Sep; 79(17):4326-4330. PubMed ID: 31481419 [TBL] [Abstract][Full Text] [Related]
33. Newer treatments for advanced hepatocellular carcinoma. Song MJ; Bae SH Korean J Intern Med; 2014 Mar; 29(2):149-55. PubMed ID: 24648795 [TBL] [Abstract][Full Text] [Related]
34. Pre- and post- operative adjuvant targeting locoregional chemotherapy combined with locoregional targeting immunostimulation and surgical resection for hepatocellular carcinoma. A new promising alternative. Lygidakis NJ; Konstantinidou T; Pothoulakis J Anticancer Res; 1994; 14(3B):1351-5. PubMed ID: 8067704 [TBL] [Abstract][Full Text] [Related]
35. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. da Motta Girardi D; Correa TS; Crosara Teixeira M; Dos Santos Fernandes G J Gastrointest Cancer; 2018 Sep; 49(3):227-236. PubMed ID: 29806062 [TBL] [Abstract][Full Text] [Related]
36. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial. Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK; BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083 [TBL] [Abstract][Full Text] [Related]
37. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460 [TBL] [Abstract][Full Text] [Related]
38. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Gong J; Chuang J; Cho M; Toomey K; Hendifar A; Li D Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718047 [TBL] [Abstract][Full Text] [Related]
39. Downstaging Hepatocellular Carcinoma before Transplantation: Role of Immunotherapy Versus Locoregional Approaches. Lindemann J; Yu J; Doyle MBM Surg Oncol Clin N Am; 2024 Jan; 33(1):143-158. PubMed ID: 37945140 [TBL] [Abstract][Full Text] [Related]
40. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Ikeda M; Morizane C; Ueno M; Okusaka T; Ishii H; Furuse J Jpn J Clin Oncol; 2018 Feb; 48(2):103-114. PubMed ID: 29253194 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]